Transition from Laser to Intravitreal Injections for Diabetic Retinopathy: Hospital Utilization and Costs from an Extended Healthcare Perspective
Open accessThe DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Purpose: To describe the trends in hospital utilization and economic outcomes associated with the transition from laser to intravitreal injection (IVI) therapy for diabetic retinopathy (DR) at Oslo University Hospital (OUH), which provides the largest retina service in Norway. Methods: This descriptive study analyzed hospital administrative data and determined the average utilization and treatment proportions of laser therapy, IVIs and vitrectomy for each patient per year. The Chi-square test was used to compare resource use between treatment groups. From an extended healthcare perspective, the annual cost per patient was calculated using Norwegian tariff data from 2020 and the National Medication Price Registry for patients seen between 2010 and 2018. Bootstrapping was performed to generate 95% confidence intervals for the cost per patient per year. Results: Among the 1838 (41% female) patients treated for DR between 2005 and 2018, OUH provided on average 1.09 laser treatments per DR patient and 0.54 vitrectomies per DR patient in 2005, whose utilization declined to 0.54 and 0.05 treatments per DR patient, respectively, by 2018. Laser treatments declined from 64% to 10%, while vitrectomies declined from 32% to 1%. In contrast, IVI treatments increased from 4.5% to 89% of the total share, representing an average increase, from 0.08 injections per patient in 2005 to 4.73 injections per patient in 2018. Both the increasing number of DR patients and the shift in the type of treatment increased the economic costs of treating DR from a total of EUR 0.605 million (EUR 2935 per patient) in 2010 to EUR 2.240 million (EUR 3665 per patient) in 2018, with IVIs contributing considerably to these costs. Conclusions: Despite the decline in the use of vitrectomies, the transition from laser to IVI therapy for DR increased the healthcare resource utilization and economic costs of its treatment over the observed time. A main cost driver was the need for long-term IVIs, in addition to the drug cost itself. Trade-offs can be achieved through effective alternative IVI delivery or appropriate drug choice that balances patient needs with the economic burden of treating DR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Costs pertaining to DR and its complications (including DMO) were combined in three studies [50, 51, 53], whereas costs in patients affected by both DR and DMO simultaneously were reported in two studies [52, 53] (Supplementary Tables 3 and 8).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a Norwegian study [50] found that the use of anti-VEGF injections in DR patients with and without DMO replaced other forms of therapy (i.e. laser therapy) and led to higher treatment costs over time.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research has suggested that the delivery of anti-VEGF injections is a major cost-driver and is expected to increase over time [12, 50, 67, 68].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, a significant number of conditions, including nAMD, DR, DMO and macular oedema secondary to RVO and mCNV, are conditions for which anti-VEGF based treatments are indicated, but only a minority of this study’s results included costs of anti-VEGF injections (n = 9 [34–36, 48–50, 54–56]).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nine articles [50–58] considered costs associated with DR and its associated complications (i.e. DMO).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [50]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Bressler, N. M., Bressler, S. B., Brucker, A. J., Ferris, F. L., Hampton, G. R., Jhaveri, C., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.022 · Cited by 1,051
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837
Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross, J. G., Glassman, A. R., Jampol, L. M., Inusah, S., Aiello, L. P., Antoszyk, A. N., Baker, C. W., Berger, B. B., Bressler, N. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.15217 · Cited by 784
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Wykoff, C. C., Abreu, F., Adamis, A. P., Basu, K., Eichenbaum, D. A., Haskova, Z., Lin, H., Loewenstein, A., Mohan, S., Pearce, I. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00018-6 · Cited by 504
A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema
(2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.05.062 · Cited by 451
Gillies, M. C., Lim, L. L., Campain, A., Quin, G. J., Salem, W., Li, J., Goodwin, S., Aroney, C., McAllister, I. L., & Fraser-Bell, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.002 · Cited by 301
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272
Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.
Caro, J. J., Ward, A. J., & O’Brien, J. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.476 · Cited by 258
The cost burden of diabetes mellitus: the evidence from Germany—the CoDiM Study
Köster, I., von Ferber, L., Ihle, P., Schubert, I., & Hauner, H. (2006) · Diabetologia · doi:10.1007/s00125-006-0277-5 · Cited by 201
Anti-vascular endothelial growth factor therapy for diabetic macular edema
Boyer, D. S., Hopkins, J. J., Sorof, J., & Ehrlich, J. S. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813512360 · Cited by 193
Brown, D. M., Wykoff, C. C., Boyer, D. S., Heier, J. S., Clark, W. L., Emanuelli, A., Higgins, P., Singer, M. A., Weinreich, D. M., Yancopoulos, G. D., et al. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.2809 · Cited by 158
Diabetic Retinopathy Screening: A Systematic Review on Patients’ Non-Attendance
Kashim, R., Newton, P., & Ojo, O. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15010157 · Cited by 128
Kiss, S., Liu, Y., Brown, J., Holekamp, N., Almony, A., Campbell, J., & Kowalski, J. (2014) · Clinical Ophthalmology · doi:10.2147/opth.s60893 · Cited by 111
Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema
Heier, J. S., Bressler, N. M., Avery, R. L., Bakri, S. J., Boyer, D. S., Brown, D. M., Dugel, P. U., Freund, K. B., Glassman, A. R., Kim, J. E., et al. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.4110 · Cited by 110
PARS PLANA VITRECTOMY FOR VITREOMACULAR TRACTION SYNDROME
Jackson, T. L., Nicod, E., Angelis, A., Grimaccia, F., Prevost, A. T., Simpson, A. R. H., & Kanavos, P. G. (2013) · Retina · doi:10.1097/iae.0b013e3182a6b3e2 · Cited by 109
OPTICAL COHERENCE TOMOGRAPHY IN RETINITIS PIGMENTOSA
García‐Martín, E., Pinilla, I., Sancho, E., Almárcegui, C., Dolz, I., Mena, D. R., Fuertes, I., & Cuenca, N. (2012) · Retina · doi:10.1097/iae.0b013e318242b838 · Cited by 103
Resource Use and Costs Associated With Diabetic Macular Edema in Elderly Persons
Shea, A. M. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.12.1748 · Cited by 86
Berrocal, M. H., & Acaba-Berrocal, L. A. (2021) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000760 · Cited by 74
Iovino, C., Mastropasqua, R., Lupidi, M., Bacherini, D., Pellegrini, M., Bernabei, F., Borrelli, E., Sacconi, R., Carnevali, A., D’Aloisio, R., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080703 · Cited by 71
Berg, K., Roald, A. B., Navaratnam, J., & Bragadóttir, R. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13522 · Cited by 69
The economic burden of diabetic retinopathy in Germany in 2002
Happich, M., Reitberger, U., Breitscheidel, L., Ulbig, M., & Watkins, J. (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0573-x · Cited by 63 · cited 1×
“For instance, in a study from Germany that analyzed DR cost from two perspectives (payer’s and societal), the total cost was 57% higher when the societal perspective was included, compared to the payer’s perspective [36].”
Teo, Z. L., Tham, Y.-C., Yu, M., Cheng, C.-Y., Wong, T. Y., & Sabanayagam, C. (2020) · Eye · doi:10.1038/s41433-020-0776-5 · Cited by 62 · cited 1×
“In this way, the contemporary preference for IVI casts a burden on both patients and healthcare institutions; the increasing shortage of ophthalmologists adds yet another burden [40,41].”
BackgroundNazari, H. K., Modarres, M., Parvaresh, M. M., & Falavarjani, K. G. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1430-x · Cited by 60
Laser Treatment in Diabetic Retinopathy
Neubauer, A. S., & ULBIG, M. W. (2007) · Ophthalmologica · doi:10.1159/000098254 · Cited by 59
Spooner, K., Guinan, G., Koller, S., Hong, T., & Chang, A. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s214098 · Cited by 52
Social determinants of health impacting adherence to diabetic retinopathy examinations
Cai, C. X., Li, Y., Zeger, S. L., & McCarthy, M. L. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002374 · Cited by 48
Management of giant retinal tear detachments
Berrocal, M. H., Chenworth, M., & Acaba, L. (2017) · Journal of Ophthalmic and Vision Research · doi:10.4103/2008-322x.200158 · Cited by 47
Matonti, F., Pommier, S., Meyer, F., Hajjar, C., Merite, P. Y., Parrat, É., Rouhette, H., Rebollo, O., & Guigou, S. (2016) · European Journal of Ophthalmology · doi:10.5301/ejo.5000787 · Cited by 43
Lode, H. E., Gjølberg, T. T., Foss, S., Sivertsen, M. S., Brustugun, J., Andersson, Y., Jørstad, Ø. K., Moe, M. C., & Andersen, J. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-54226-7 · Cited by 40
Self-citationSarohia, G. S., Nanji, K., Khan, M. D., Khalid, M. F., Rosenberg, D., Deonarain, D. M., Phillips, M., Thabane, L., Kaiser, P. K., Garg, S. J., et al. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.04.003 · Cited by 36
A Practical Manual of Diabetic Retinopathy Management
Scanlon, P. H., Wilkinson, C. P., Aldington, S. J., & Matthews, D. R. (2009) · Wiley eBooks · doi:10.1002/9781444308174 · Cited by 36
Importance of medication adherence in treatment needed diabetic retinopathy
Kao, C.-C., Hsieh, H., Lee, D. Y., Hsieh, K., & Sheu, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-98488-6 · Cited by 35
Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice
Giocanti‐Auregan, A., Tadayoni, R., Grenet, T., Fajnkuchen, F., Nghiem‐Buffet, S., Delahaye-Mazza, C., Quentel, G., & Cohen, S. Y. (2016) · BMC Ophthalmology · doi:10.1186/s12886-016-0317-y · Cited by 32
Bonora, E., Cataudella, S., Marchesini, G., Miccoli, R., Vaccaro, O., Fadini, G. P., Martini, N., & Rossi, E. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001191 · Cited by 30
Prevalence of diabetic retinopathy in Norway: report from a screening study
Kilstad, H. N., Sjølie, A. K., Gøransson, L. G., Hapnes, R., Henschien, H. J., Alsbirk, K. E., Fossen, K., Bertelsen, G., Holstad, G., & Bergrem, H. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02160.x · Cited by 27
Glassman, A. R., Beaulieu, W. T., Maguire, M. G., Antoszyk, A. N., Chow, C. C., Elman, M. J., Jampol, L. M., Salehi-Had, H., Sun, J. K., & DRCR Retina Network (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.1110 · Cited by 26
COMPARATIVE EFFECTIVENESS OF ANTI-VEGF AGENTS FOR DIABETIC MACULAR EDEMA
Ollendorf, D. A., Colby, J. A., & Pearson, S. D. (2013) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462313000500 · Cited by 24
Eichenbaum, D. A., Duerr, E. J., Patel, H. R., & Pollack, S. M. (2018) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20181101-17 · Cited by 18
Patient preferences in the treatment of diabetic retinopathy
Grinspan (2011) · Patient Preference and Adherence · doi:10.2147/ppa.s11972 · Cited by 17
Park, K. H., Kim, Y. Y., Jo, Y. J., Oh, J., Lee, J. E., Lee, J. E., Park, D. H., Kang, S. W., Lee, W. K., Kim, H. K., et al. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e118 · Cited by 15
Muchira, J. M., Stuart‐Shor, E., Kariuki, J. K., Mukuna, A., Ndigirigi, I. W., Gakage, L., Mutuma, V., & Karani, A. K. (2015) · International Journal of Africa Nursing Sciences · doi:10.1016/j.ijans.2015.09.002 · Cited by 13
Okoye, O., Okonkwo, O. N., Oderinlo, O., Hassan, K., & Ijasan, A. (2016) · Nigerian Journal of Clinical Practice · doi:10.4103/1119-3077.183313 · Cited by 12
Future opportunities in diabetic retinopathy research
Gardner, T. W., & Chew, E. Y. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000238 · Cited by 11
Mason, L., Crosson, J. N., Mason, J. O., & McGwin, G. (2017) · Journal of Ophthalmology · doi:10.1155/2017/7398470 · Cited by 11
Tóth, G., Limburg, H., Szabó, D., Sándor, G. L., Nagy, Z. Z., & Németh, J. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316337 · Cited by 11
Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?
Chia, M. A., & Keane, P. A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00105-2 · Cited by 10
Memon, S., Ahsan, S., Alvi, R., Fawwad, A., Basit, A., Shera, S., Sheikh, S. A., & Fahim, M. F. (2015) · PubMed · doi:10.2015/jcpsp.743746 · Cited by 6
Situational analysis of diabetic retinopathy treatment Services in Ghana
Mensah-Debrah, A., Amissah-Arthur, K. N., Kumah, D. B., Akuffo, K. O., Duah, I. O., & Bascarán, C. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06608-9 · Cited by 6
Sun, J. K. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0201-3 · Cited by 5
Hertzberg, S. N. W., Moe, M. C., Jørstad, Ø. K., Petrovski, B. É., Burger, E. A., & Petrovski, G. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15151 · Cited by 4
Self-citation
Research works printed but not linked: 3
- European Society of Cardiology (ESC) Global Statistics on Diabetes, ESC Press Office. Available online: https://www.escardio.org/Education/Diabetes-and-CVD/Recommended-Reading/global-statistics-on-diabetes.
- Singer, 2012, Effect of Combination Therapy with Bevacizumab and Dexamethasone Intravitreal Implant in Patients with Retinal Vein Occlusion, Retina, 32, 1289
- Haas, M., and Hall, J. (2015). The Economic Evaluation of Health Care, Oxford University Press.
Cited by
Oxidative Stress and Its Regulation in Diabetic Retinopathy
Haydinger, C. D., Oliver, G. F., Ashander, L. M., & Smith, J. R. (2023) · Antioxidants · doi:10.3390/antiox12081649 · Cited by 105
“The advent of intravitreal anti-VEGF drugs such as ranubizumab and aflibercept heralded an age of unprecedented benefit for those with center-involving diabetic macular edema, but due to short treatment intervals and the need for close monitoring, this created extreme demand on resources [42,43].”
Potential of Sulodexide in the Treatment of Diabetic Retinopathy and Retinal Vein Occlusion
Böhm, E. W., Buonfiglio, F., Korb, C. A., Dauth, A., Pfeiffer, N., Bręborowicz, A., & Gericke, A. (2024) · Thrombosis and Haemostasis · doi:10.1055/s-0044-1791232 · Cited by 12
“105 – 107 Additionally, the need for multiple injections and long-term follow-up imposes a burden on patients and their caregivers.”
Chihara, E. (2023) · Clinical ophthalmology · doi:10.2147/opth.s431060 · Cited by 3
Cost-Effectiveness of Alternative Treatment Strategies of Subretinal Macular Hemorrhage
Confalonieri, F., Hertzberg, S. N. W., Dziedzic, K. A., Lumi, X., Lytvynchuk, L. M., Znaor, L., Petrovski, G., & Petrovski, B. É. (2025) · Healthcare · doi:10.3390/healthcare13131550 · Cited by 2
“Most existing economic evaluations in ophthalmology have largely focused on anti-VEGF therapy’s cost–utility for AMD or surgical approaches, such as vitrectomy, with models demonstrating variable incremental cost-effectiveness ratios [15–18].”
Self-citationThe Prevalence of Diabetic Retinopathy in the 21st Century: New Insights From a Portuguese Center
Martins, P. M., Leite, S., Teixeira, S., Cabanas, J. C., Silva, L., & Neves, F. (2025) · Cureus · doi:10.7759/cureus.85501 · Cited by 2
“…hours, and with the progressive shift towards treatment with intravitreal injections, the cost per treated DR patient has significantly risen in the past two decades: a recently published study in an hospital in Oslo estimates this metric has changed from €2,935 in 2010 to €3,665 in 2018 [8].”
Metadata
- Authors
- Hertzberg, S. N. W., Jørstad, Ø. K., Petrovski, B. É., Bragadottir, R., Steffensen, L. A., Moe, M. C., Burger, E. A., & Petrovski, G.
- Affiliations
- University of Oslo (NO)
- Oslo University Hospital (NO)
- Center for Eye Research, Department of Ophthalmology, Institute for Clinical Medicine, University of Oslo, 0450 Oslo, Norway
- Harvard University (US)
- Corresponding author
- Petrovski, Goran
- ORCID
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2022-10-02
- Volume
- 19
- Issue
- 19
- Pages
- 12603
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC9564656
- OpenAlex
- W4303696557
- Cited by
- 6
- References
- 51
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 2
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Funders
- Baltic Research Programme of the European Economic Area (EEZ/BPP/VIAA/2021/8)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- diabetic retinopathy, intravitreal injection, laser photocoagulation, vitrectomy, hospital utilization, health care costs, treatment trends, cost drivers, drug costs, retinal disease management, Norway, Oslo University Hospital, cost-effectiveness trade-off, drug selection, quality of life
- MeSH terms
- Delivery of Health Care, Diabetes Mellitus, Diabetic Retinopathy, Female, Hospitals, Humans, Lasers, Male, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.